1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2022, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 18, 2, 2, 61 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 11 and 2 molecules, respectively.
Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Retinitis Pigmentosa (Retinitis) - Overview
- Retinitis Pigmentosa (Retinitis) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
- Retinitis Pigmentosa (Retinitis) - Drug Profiles
- Retinitis Pigmentosa (Retinitis) - Dormant Projects
- Retinitis Pigmentosa (Retinitis) - Discontinued Products
- Retinitis Pigmentosa (Retinitis) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Retinitis Pigmentosa (Retinitis) - Dormant Projects, 2022
- Retinitis Pigmentosa (Retinitis) - Dormant Projects, 2022 (Contd..2)
- Retinitis Pigmentosa (Retinitis) - Discontinued Products, 2022
- Number of Products under Development for Retinitis Pigmentosa (Retinitis), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics Inc
- AbbVie Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Alpine Biotherapeutics Corp
- Anida Pharma Inc
- Ankar Pharma SL
- Applied Genetic Technologies Corp
- Astellas Pharma Inc
- Bayon Therapeutics Inc
- Beijing Chinagene Tech Co Ltd
- Biogen Inc
- Brighton Biotech Inc
- Casebia Therapeutics LLP
- CIRC Biosciences Inc
- Coave Therapeutics
- Copernicus Therapeutics Inc
- Curative Biotechnology Inc
- Daewoong Pharmaceutical Co Ltd
- Dompe Farmaceutici SpA
- DTx Pharma Inc
- Editas Medicine Inc
- EmendoBio Inc
- Endogena Therapeutics Inc
- Epicrispr Biotechnologies Inc
- EyePoint Pharmaceuticals Inc
- Eyestem Research Pvt Ltd
- Eyevensys SAS
- GenSight Biologics SA
- Graybug Vision Inc
- Grupo Ferrer Internacional SA
- ID Pharma Co Ltd
- InFlectis BioScience SAS
- IVERIC bio Inc
- jCyte Inc
- Kala Pharmaceuticals Inc
- Kubota Vision Inc
- Limnopharma SL
- Lineage Cell Therapeutics Inc
- Locanabio Inc
- MeiraGTx Holdings Plc
- MimeTech Srl
- Mitochem Therapeutics, LLC
- Nanoscope Therapeutics Inc
- Nanovector srl
- Navega Therapeutics Inc
- Novartis AG
- Ocugen Inc
- OiDE OptoEye Inc
- OliX Pharmaceuticals Inc
- ONL Therapeutics Inc
- Opsis Therapeutics LLC
- OptiKira LLC
- Perceive Biotherapeutics Inc
- Profarma
- Prolindox Inc
- ProQR Therapeutics NV
- PYC Therapeutics Ltd
- Ray Therapeutics Inc
- ReNeuron Group Plc
- ResQ Biotech
- Restore Vision Co Ltd
- Ripple therapeutics Corp
- Rznomics Inc
- Saliogen Therapeutics Inc
- SanBio Co Ltd
- SparingVision SAS
- Staidson BioPharma Inc
- Sumitomo Pharma Co Ltd
- SunRegen Healthcare AG
- Suzhou Ugenex Therapeutics Ltd Co
- Sylentis SAU
- Variant
- ViGeneron GmbH
- Viridian Therapeutics Inc
- Wave Life Sciences Ltd
- Worphmed Srl
